uniQure
Meibergdreef 61
Amsterdam
1105 BA
Tel: 31-20-566-7394
Fax: 31-20-566-9272
Website: http://www.uniqure.com/
Email: info@uniQure.com
129 articles with uniQure
-
BioSpace Global Roundup, Sept. 5
9/5/2019
Companies from across Europe and Asia share updates on their business and pipelines. -
uniQure Announces Achievement of Planned Enrollment in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Patients with Hemophilia B
9/3/2019
uniQure N.V. announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
-
BioSpace Global Roundup, July 11
7/11/2019
Companies from across Europe, Asia and around the globe share pipeline and business updates. -
uniQure Announces 36 Weeks of Follow-Up Data from Phase IIb Study of AMT-061 and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia B
7/6/2019
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced updated clinical data on the three patients treated in the Company’s ongoing Phase IIb study of AMT-061, an investigational AAV5-based gene therapy containing a patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B
-
A report about Amsterdam-based uniQure indicated it is looking at various options, including a potential sale. As a result, company stock jumped as much as 10% in premarket trading.
-
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a lo...
-
After Earlier Dramatic Gene Therapy Collapse, uniQure's Hemophilia B Therapy Showing Promise
2/8/2019
Based in Lexington, Mass. and Amsterdam, The Netherlands, uniQure updated its Phase IIb trial of AMT-061 in hemophilia B. AMT-061 is an AAV5-based gene therapy that contains a FIX-Padua variant, meaning a patent-protected form of Factor IX, the missing or insufficient protein that results in the ... -
Across the globe, pharma companies are making an impact. Last week BioSpace launched the first of a weekly roundup of international biotech and pharma news. Here's the latest edition.
-
uniQure Announces First Patient Treated in Dose-Confirmation Study of AMT-061 in Patients with Hemophilia B
8/23/2018
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe unmet medical needs, today announced that it has treated the first patient in its Phase IIb dose-confirmation study of AMT-061, an investigational AAV5-based gene therapy incorporating the FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
-
uniQure Announces Second Quarter 2018 Financial Results and Highlights Company Progress
8/8/2018
Patient Enrollment Underway in Global Phase III HOPE-B Pivotal Study of AMT-061
-
It feels like we’re standing on the edge of a precipice. Despite the ho-hum recent performance of biotech stocks, amazing things are about to happen. And one of the most amazing of all is gene therapy.
-
As the European Medicines Agency prepares to make Amsterdam its new home following the U.K.’s Brexit, Holland is likely to see its biopharma industry snag a hoped-for boost in new business due to the presence of the regulatory agency.
-
uniQure Presents New Data Demonstrating Clinical Benefit in Hemophilia B Patients with Pre-Existing Anti-AAV5 Neutralizing Antibodies
5/22/2018
uniQure N.V. presented data showing successful liver transduction with the AAV5 vector in both non-human primates and humans with pre-existing anti-AAV5 neutralizing antibodies (NABs).
-
Hemophilia B patients have some good news to cheer. Data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of patients. However, uniQure wasn’t the only company touting positive news in the treatment of hemophilia.
-
coreHEM Publishes Core Outcome Set for Hemophilia Clinical Trials; Prepares to Launch Next Phase of Work
5/21/2018
The coreHEM initiative has announced the publication of a core outcome set for clinical trials of gene therapy in hemophilia.
-
During the 2016 U.S. presidential election, the push for lower drug prices became one of the hot-button topics. Now there appears to be some efforts by advocacy groups and government entities to tackle the subject in several different ways.
-
uniQure Announces Updated, Long-Term Clinical Data From Ongoing Phase I/II Trial of AMT-060 in Patients With Severe Hemophilia B
12/11/2017
The data includes up to two years of follow-up from the low-dose cohort and up to 18 months of follow-up from the second, higher-dose cohort.
-
The company plans to expeditiously advance AMT-061 instead of AMT-060.
-
uniQure: A Busted Biotech IPO Worth Owning
8/22/2017
-
uniQure Announces The Successful Development And Scale-Up Of Manufacturing Processes For Its Hemophilia B Gene Therapy Program
7/21/2017